View Financial HealthLadRx 配当と自社株買い配当金 基準チェック /06LadRx配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 16LadRx Corporation Announces Resignation of Joel Caldwell from the Board of Directors and All Board Committees, Effective as of April 15, 2025LadRx Corporation announced on April 14, 2025, Joel Caldwell tendered his resignation from the board of directors of the company and all Board committees thereto, effective as of April 15, 2025. Mr. Caldwell’s resignation was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.お知らせ • Aug 21LadRx Corporation, Annual General Meeting, Oct 04, 2024LadRx Corporation, Annual General Meeting, Oct 04, 2024. Location: 11726 san vicente blvd, suite 650, ca 90049, los angeles United Statesお知らせ • Jul 29LadRx Corporation, Annual General Meeting, Sep 06, 2023LadRx Corporation, Annual General Meeting, Sep 06, 2023, at 10:00 Pacific Daylight. Location: 11726 San Vicente Boulevard, Suite 650, Los Angeles California United States Agenda: To consider the election of one Class II director to serve until the 2026 Annual Meeting of Stockholders; to consider the approval to amend the Company’s governing documents (Restated Certificate of Incorporation and By-Laws) to declassify the structure of the Board, such that each director standing for election shall only be eligible to be elected for one-year terms; to consider the ratification of the appointment of Weinberg & Company as company's independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider the approval, on an advisory basis, the compensation of company's named executive officers as disclosed in this Proxy Statement; to consider the approval, on an advisory, basis, regarding the frequency of future stockholder advisory votes to approve the compensation of company's named executive officers; and to consider other matters.お知らせ • Oct 08CytRx Corporation Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’S Pancreatic CancerCytRx Corporation announced that it has highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio Inc. and NantKwest Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.お知らせ • Sep 30Cytrx Corporation, Advanced Bioscience Laboratories and University of Massachusetts Announce First Patients Enrolled in Hiv Vaccine TrialCytRx Corp. Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine developed by the University of Massachusetts Medical School and ABL and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The clinical trial, whose primary objective is to determine the safety and tolerability of the multiple dosing levels of the polyvalent vaccine. The trial will enroll 36 people who do not have HIV. The vaccine contains only portions of the HIV genome and, therefore, individuals receiving inoculations cannot get HIV from the vaccine. Volunteers' given the DNA and protein boost vaccine, will be carefully monitored for any adverse effects, and will also have samples collected in order to measure immune responses over time.お知らせ • Sep 18CytRx Corporation Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type CCytRx Corporation highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority Review, the company’s New Drug Application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety, effectiveness, diagnosis or prevention of serious conditions. This designation shortens the review period from the standard 10 months to 6 months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (“PDUFA”) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. Arimoclomol was previously granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application with the European Medicines Agency for arimoclomol in NPC in H2 2020.決済の安定と成長配当データの取得安定した配当: LADXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: LADXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場LadRx 配当利回り対市場LADX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (LADX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Biotechs)2.4%アナリスト予想 (LADX) (最長3年)n/a注目すべき配当: LADXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: LADXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: LADXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: LADXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 16:45終値2026/05/19 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LadRx Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Ashok KumarAegis Capital CorporationMorris AjzenmanGriffin SecuritiesAndrew FeinH.C. Wainwright & Co.5 その他のアナリストを表示
お知らせ • Apr 16LadRx Corporation Announces Resignation of Joel Caldwell from the Board of Directors and All Board Committees, Effective as of April 15, 2025LadRx Corporation announced on April 14, 2025, Joel Caldwell tendered his resignation from the board of directors of the company and all Board committees thereto, effective as of April 15, 2025. Mr. Caldwell’s resignation was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
お知らせ • Aug 21LadRx Corporation, Annual General Meeting, Oct 04, 2024LadRx Corporation, Annual General Meeting, Oct 04, 2024. Location: 11726 san vicente blvd, suite 650, ca 90049, los angeles United States
お知らせ • Jul 29LadRx Corporation, Annual General Meeting, Sep 06, 2023LadRx Corporation, Annual General Meeting, Sep 06, 2023, at 10:00 Pacific Daylight. Location: 11726 San Vicente Boulevard, Suite 650, Los Angeles California United States Agenda: To consider the election of one Class II director to serve until the 2026 Annual Meeting of Stockholders; to consider the approval to amend the Company’s governing documents (Restated Certificate of Incorporation and By-Laws) to declassify the structure of the Board, such that each director standing for election shall only be eligible to be elected for one-year terms; to consider the ratification of the appointment of Weinberg & Company as company's independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider the approval, on an advisory basis, the compensation of company's named executive officers as disclosed in this Proxy Statement; to consider the approval, on an advisory, basis, regarding the frequency of future stockholder advisory votes to approve the compensation of company's named executive officers; and to consider other matters.
お知らせ • Oct 08CytRx Corporation Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’S Pancreatic CancerCytRx Corporation announced that it has highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio Inc. and NantKwest Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.
お知らせ • Sep 30Cytrx Corporation, Advanced Bioscience Laboratories and University of Massachusetts Announce First Patients Enrolled in Hiv Vaccine TrialCytRx Corp. Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine developed by the University of Massachusetts Medical School and ABL and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The clinical trial, whose primary objective is to determine the safety and tolerability of the multiple dosing levels of the polyvalent vaccine. The trial will enroll 36 people who do not have HIV. The vaccine contains only portions of the HIV genome and, therefore, individuals receiving inoculations cannot get HIV from the vaccine. Volunteers' given the DNA and protein boost vaccine, will be carefully monitored for any adverse effects, and will also have samples collected in order to measure immune responses over time.
お知らせ • Sep 18CytRx Corporation Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type CCytRx Corporation highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority Review, the company’s New Drug Application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety, effectiveness, diagnosis or prevention of serious conditions. This designation shortens the review period from the standard 10 months to 6 months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (“PDUFA”) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. Arimoclomol was previously granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application with the European Medicines Agency for arimoclomol in NPC in H2 2020.